Brief: Precision Biosciences Receives FDA Rare Pediatric Disease
25/06/2025 12:01
June 25 (Reuters) - Precision BioSciences Inc DTIL.O: PRECISION BIOSCIENCES RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR PBGENE-DMD FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Source text: ID:nBwc1Vhyla Further company coverage: DTIL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Precision Biosciences
See all newsPrecision BioSciences Inc reports results for the quarter ended June 30 - Earnings Summary
Precision BioSciences Q2 net loss widens on warrant liability charge
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Precision Biosciences - Enters First Amendment To Loan And Security Agreement With Banc Of California - SEC Filing